MX2018004605A - Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo-[1,2- a]-pirrolo-[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)-pirrolid in-1-carboxamida y formas en estado solido de la misma. - Google Patents

Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo-[1,2- a]-pirrolo-[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)-pirrolid in-1-carboxamida y formas en estado solido de la misma.

Info

Publication number
MX2018004605A
MX2018004605A MX2018004605A MX2018004605A MX2018004605A MX 2018004605 A MX2018004605 A MX 2018004605A MX 2018004605 A MX2018004605 A MX 2018004605A MX 2018004605 A MX2018004605 A MX 2018004605A MX 2018004605 A MX2018004605 A MX 2018004605A
Authority
MX
Mexico
Prior art keywords
pyrazin
pyrrolo
imidazo
trifluoroethyl
carboxamide
Prior art date
Application number
MX2018004605A
Other languages
English (en)
Inventor
Y Sheikh Ahmad
M Mulhern Mathew
T Mayer Peter
D Allian Ayman
Jayanth Jayanthy
Eslam F Mohamed Mohamed-
F Nordstroem Lars
A Othman Ahmed
J Rozema Michael
Bhagavatula Lakshmi
J Marroum Patrick
B Borchardt Thomas
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57209916&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2018004605(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of MX2018004605A publication Critical patent/MX2018004605A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

La presente descripción se refiere a procesos para la preparación de (3S,4R)-3-etil-4-(3H-imidazo-[1,2-a]-pirrolo-[2,3-e]-pirazin-8- il)-N-(2,2, 2-trifluoro-etil)-pirrolidin-1-carboxamid a, a las formas en estado sólido de la misma, y a las composiciones farmacéuticas correspondientes, a los métodos de tratamiento (incluyendo el tratamiento de artritis reumatoide), kits, métodos de síntesis, y subproductos del proceso.
MX2018004605A 2015-10-16 2016-10-17 Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo-[1,2- a]-pirrolo-[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)-pirrolid in-1-carboxamida y formas en estado solido de la misma. MX2018004605A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562242797P 2015-10-16 2015-10-16
US201562267672P 2015-12-15 2015-12-15
US201662301537P 2016-02-29 2016-02-29
US201662352380P 2016-06-20 2016-06-20
PCT/US2016/057372 WO2017066775A1 (en) 2015-10-16 2016-10-17 PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF

Publications (1)

Publication Number Publication Date
MX2018004605A true MX2018004605A (es) 2018-11-29

Family

ID=57209916

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2018004605A MX2018004605A (es) 2015-10-16 2016-10-17 Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo-[1,2- a]-pirrolo-[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil)-pirrolid in-1-carboxamida y formas en estado solido de la misma.
MX2021013812A MX2021013812A (es) 2015-10-16 2018-04-13 Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo[1,2-a ]pirrolo[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil) pirrolidin-1-carboxamida y formas en estado solido de la misma.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021013812A MX2021013812A (es) 2015-10-16 2018-04-13 Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo[1,2-a ]pirrolo[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil) pirrolidin-1-carboxamida y formas en estado solido de la misma.

Country Status (14)

Country Link
US (34) US20170129902A1 (es)
EP (2) EP3362455A1 (es)
JP (4) JP6770775B2 (es)
KR (1) KR20180081523A (es)
CN (4) CN116270646A (es)
AU (3) AU2016340167B2 (es)
BR (2) BR112018007677A2 (es)
CA (2) CA3123260A1 (es)
HK (1) HK1263380A1 (es)
IL (2) IL258654A (es)
MX (2) MX2018004605A (es)
RU (1) RU2018117889A (es)
SG (8) SG10201913987UA (es)
WO (1) WO2017066775A1 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2836833A1 (de) 1978-08-23 1980-04-10 Volkswagenwerk Ag Brennkraftmaschine mit in zwei reihen angeordneten zylindern
CN102711476B (zh) 2009-12-01 2014-12-03 Abbvie公司 新的三环化合物
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11773106B2 (en) 2015-10-16 2023-10-03 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3362455A1 (en) 2015-10-16 2018-08-22 AbbVie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
CA3052873A1 (en) 2017-03-09 2018-09-13 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US20210163409A1 (en) * 2017-07-19 2021-06-03 Dr. Reddy's Laboratories Limited Alternate processes for the preparation of pyrrolidine derivatives
IL302865A (en) 2018-03-30 2023-07-01 Incyte Corp Use of JAK inhibitors to treat hidradenitis suppurativa
EP3845521A4 (en) * 2018-08-31 2022-08-24 Suzhou Pengxu Pharmatech Co., Ltd. METHODS OF SYNTHESIS FOR UPADACITINIB AND INTERMEDIATE THEREOF
CN110872250B (zh) * 2018-08-31 2023-01-10 苏州鹏旭医药科技有限公司 两种化合物及其制备方法和在合成乌西替尼中的用途
WO2020063939A1 (zh) * 2018-09-29 2020-04-02 苏州科睿思制药有限公司 一种Upadacitinib的晶型及其制备方法和用途
CN111217819B (zh) * 2018-11-27 2021-05-14 杭州科巢生物科技有限公司 乌帕替尼的合成方法
EP3891151A1 (en) 2018-12-05 2021-10-13 LEK Pharmaceuticals d.d. Crystalline phosphate salt of selective jak1 inhibitor upadacitinib
CN109369659B (zh) * 2018-12-06 2020-10-27 浙江师范大学 一种jak抑制剂的合成方法
WO2020115213A1 (en) 2018-12-07 2020-06-11 Lek Pharmaceuticals D.D. Solvate of a selective jak1 inhibitor
CN109705011B (zh) * 2019-01-18 2021-02-19 浙江师范大学 一种乌帕替尼中间体的合成方法及中间体
CN112888692A (zh) * 2019-03-01 2021-06-01 苏州科睿思制药有限公司 一种Upadacitinib的晶型及其制备方法和用途
WO2020202183A1 (en) 2019-03-29 2020-10-08 Mylan Laboratories Limited The process for the preparation of upadacitinib and its intermediates
CN111909160A (zh) 2019-05-09 2020-11-10 苏州鹏旭医药科技有限公司 一种乌帕替尼盐类化合物及其制备方法
CN110229160A (zh) * 2019-06-11 2019-09-13 南京新酶合医药科技有限公司 (5-甲苯磺酰基-5H-吡咯并[2,3-b]吡嗪-2-基)氨基甲酸乙酯的制备方法
CN110117245B (zh) * 2019-06-21 2021-03-02 浙江师范大学 一种jak抑制剂中间体的合成方法
WO2021005484A1 (en) * 2019-07-11 2021-01-14 Mankind Pharma Ltd. Pyrrolidine compounds, its salt and use in the preparation of upadacitinib thereof
CN110615753A (zh) * 2019-09-02 2019-12-27 南京新酶合医药科技有限公司 一种(3r,4s)-1-取代-4-乙基吡咯-3-羧酸的合成方法
WO2021067465A1 (en) 2019-09-30 2021-04-08 Abbvie Inc. Treating spondyloarthritic and psoriatic conditions with upadacitinib
CN111072543B (zh) * 2019-11-13 2021-06-04 北京海美桐医药科技有限公司 一种(3r,4s)-4-乙基吡咯烷-3-羧酸类化合物的制备方法及其应用
JP2023510111A (ja) 2019-12-19 2023-03-13 クリア、スペイン、エセ、ア、ウ ウパダシチニブの調製のための方法及び中間体
WO2021176473A1 (en) * 2020-03-05 2021-09-10 Mylan Laboratories Limited A process for the preparation of upadacitinib and its intermediates
CN114206877B (zh) * 2020-06-05 2024-04-19 苏州科睿思制药有限公司 一种乌帕替尼的晶型及其制备方法和用途
KR20230038229A (ko) * 2020-07-08 2023-03-17 크리스탈 파마슈티컬 (쑤저우) 씨오., 엘티디. 우파다시티닙의 결정형, 이의 제조 방법 및 이의 용도
WO2022044037A1 (en) 2020-08-24 2022-03-03 Mylan Laboratories Limited An improved process for the preparation of upadacitinib intermediate
BR112023020826A2 (pt) * 2021-04-07 2023-12-12 Abbvie Inc Cocristais de upadacitinibe
CN114380837B (zh) * 2021-12-27 2023-06-30 上海邈金医药科技有限公司 一种具有Janus激酶抑制活性的化合物、包括该化合物的组合物及其应用
WO2023131978A1 (en) * 2022-01-06 2023-07-13 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of upadacitinib
WO2023138804A1 (en) 2022-01-20 2023-07-27 Renata Pharmaceutical (Ireland) Limited Sustained release pharmaceutical composition of upadacitinib
EP4215196A1 (en) 2022-01-24 2023-07-26 Abivax Combination of 8-chloro-n-(4-(trifluoromethoxy)phenyl)quinolin-2-amine and its derivatives with a jak inhibitor
WO2024075131A1 (en) * 2022-10-03 2024-04-11 Natco Pharma Limited Co-crystal of upadacitinib and diacetyl-d-tartaric acid and process for the preparation thereof
CN117285535B (zh) * 2023-11-27 2024-02-02 中节能万润股份有限公司 一种乌帕替尼中间体及成盐中间体的制备方法
CN117285537B (zh) * 2023-11-27 2024-02-06 中节能万润股份有限公司 一种乌帕替尼的制备方法
CN117285536B (zh) * 2023-11-27 2024-02-20 中节能万润股份有限公司 一种乌帕替尼中间体的制备方法
CN117447481A (zh) * 2023-12-23 2024-01-26 潍坊医学院 一种乌帕替尼-焦谷氨酸盐的无定形物及其制备方法与应用

Family Cites Families (128)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB716327A (en) 1951-09-05 1954-10-06 Ici Ltd New heterocyclic compounds
US3663559A (en) 1969-12-03 1972-05-16 Union Carbide Corp Preparation of oxo-furo-pyridines from furylvinyl isocyanates
ZA737247B (en) 1972-09-29 1975-04-30 Ayerst Mckenna & Harrison Rapamycin and process of preparation
US4053474A (en) 1976-04-21 1977-10-11 E. R. Squibb & Sons, Inc. Pyrazolo[4,3-e][1,2,4]triazolo[4,3-c]pyrimidine
US5605690A (en) 1989-09-05 1997-02-25 Immunex Corporation Methods of lowering active TNF-α levels in mammals using tumor necrosis factor receptor
ATE195739T1 (de) 1989-10-20 2000-09-15 Kyowa Hakko Kogyo Kk Kondensierte purinderivate
ATE271064T1 (de) 1990-01-11 2004-07-15 Isis Pharmaceuticals Inc Oligonukleotidderivate zur detektieren und modulation von rna aktivität und genexpression
US6262241B1 (en) 1990-08-13 2001-07-17 Isis Pharmaceuticals, Inc. Compound for detecting and modulating RNA activity and gene expression
AU668864B2 (en) 1991-03-18 1996-05-23 Centocor Inc. Chimeric antibodies specific for human tumor necrosis factor
KR100207360B1 (ko) 1991-06-14 1999-07-15 돈 더블유. 슈미츠 이미다조[1,5,-a]퀸옥살린
US5212310A (en) 1991-12-19 1993-05-18 Neurogen Corporation Certain aryl fused imidazopyrimidines; a new class of GABA brain receptor ligands
US5266698A (en) 1992-04-30 1993-11-30 Neurogen Corporation Certain aryl and cycloalkyl fused imidazopyrazinediones; a new class of GABA brain receptor ligands
US5306819A (en) 1992-08-27 1994-04-26 Neurogen Corporation Certain aryl a cycloalkyl fused imidazopyrazinols; and new class of GABA brain receptor ligands
EP1005870B1 (en) 1992-11-13 2009-01-21 Biogen Idec Inc. Therapeutic application of chimeric antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
EP0686157A1 (en) 1993-02-26 1995-12-13 Schering Corporation 2-benzyl-polycyclic guanine derivatives and process for preparing them
US5733905A (en) 1993-07-29 1998-03-31 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
US5736540A (en) 1993-07-29 1998-04-07 American Cyanamid Company Tricyclic diazepine vasopressin antagonists and oxytocin antagonists
IL112248A0 (en) 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
US5547975A (en) 1994-09-20 1996-08-20 Talley; John J. Benzopyranopyrazolyl derivatives for the treatment of inflammation
RU2158127C2 (ru) 1994-12-23 2000-10-27 Варнер-Ламберт Компани Способы ингибирования тирозинкиназы рецептора эпидермального фактора роста, азотсодержащие трициклические соединения, фармацевтическая композиция, предназначенная для введения ингибитора тирозинкиназы рецептора эпидермального фактора роста, например, erb-b2, erb-b3 или erb-b4, и противозачаточная композиция
US5753648A (en) 1995-01-17 1998-05-19 American Cyanamid Company Tricyclic benzazepine vasopressin antagonists
US5521173A (en) 1995-01-17 1996-05-28 American Home Products Corporation Tricyclic benzazepine vasopressin antagonists
US5763137A (en) 1995-08-04 1998-06-09 Agfa-Gevaert, N.V. Method for making a lithographic printing plate
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
FR2742676B1 (fr) 1995-12-21 1998-02-06 Oreal Nanoemulsion transparente a base de tensioactifs silicones et utilisation en cosmetique ou en dermopharmacie
US5703244A (en) 1996-11-21 1997-12-30 Abbott Laboratories Process for preparation of chiral 3-amino-pyrrolidine and analogous bicyclic compounds
CA2279198C (en) 1997-02-05 2009-04-14 Merck & Co., Inc. Process for the crystallization of a reverse transcriptase inhibitor using an anti-solvent
AU756838B2 (en) 1998-03-04 2003-01-23 Bristol-Myers Squibb Company Heterocyclo-substituted imidazopyrazine protein tyrosine kinase inhibitors
ATE280154T1 (de) 1998-09-14 2004-11-15 Warner Lambert Co Verzweigte alkylpyrrolidin-3-carbonsäuren
US6448253B1 (en) 1998-09-16 2002-09-10 King Pharmaceuticals Research And Development, Inc. Adenosine A3 receptor modulators
DE19853665B4 (de) 1998-11-20 2005-06-30 Siemens Ag Fahrzeugkommunikationssystem und Verfahren zum Austausch von Daten in einem Kraftfahrzeug
CO5271670A1 (es) 1999-10-29 2003-04-30 Pfizer Prod Inc Antagonistas del factor de liberacion de corticitropina y composiciones relacionadas
TWI271406B (en) 1999-12-13 2007-01-21 Eisai Co Ltd Tricyclic condensed heterocyclic compounds, preparation method of the same and pharmaceuticals comprising the same
MXPA03001186A (es) 2000-08-07 2004-04-20 Neurogen Corp Compuestos heterociclicos como ligandos del receptor acido gamma aminobutirico (gabaa).
GB0115393D0 (en) 2001-06-23 2001-08-15 Aventis Pharma Ltd Chemical compounds
GB0124299D0 (en) 2001-10-10 2001-11-28 Astrazeneca Ab Crystal structure of enzyme and uses thereof
ATE353013T1 (de) 2002-02-19 2007-02-15 Pfizer Italia Srl Trizyklische pyrazolderivate, verfahren zu ihrer herstellung und ihre verwendung als antitumor mittel
US20030181488A1 (en) 2002-03-07 2003-09-25 Boehringer Ingelheim Pharma Gmbh & Co. Kg Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof
TW200400034A (en) 2002-05-20 2004-01-01 Bristol Myers Squibb Co Pyrazolo-pyrimidine aniline compounds useful as kinase inhibitors
EP1560582A4 (en) 2002-10-09 2008-03-12 Scios Inc AZAINDOL DERIVATIVES AS INHIBITORS OF THE p38 KINASE
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
EP1460088A1 (en) 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
AR044510A1 (es) 2003-04-14 2005-09-14 Merck & Co Inc Procedimiento e intermedios para preparar acidos carboxilicos de pirrolidina
US7176214B2 (en) 2003-05-21 2007-02-13 Bristol-Myers Squibb Company Imidazo-fused oxazolo[4,5-β]pyridine and imidazo-fused thiazolo[4,5-β]pyridine based tricyclic compounds and pharmaceutical compositions comprising same
US7169926B1 (en) 2003-08-13 2007-01-30 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
ES2318343T3 (es) 2003-10-09 2009-05-01 Abbott Laboratories Derivados de pirrolidinil urea como inhibidores de la angiogenesis..
US7592466B2 (en) 2003-10-09 2009-09-22 Abbott Laboratories Ureas having antiangiogenic activity
CA2566158A1 (en) 2004-05-14 2005-11-24 Abbott Laboratories Kinase inhibitors as therapeutic agents
AR049300A1 (es) 2004-06-15 2006-07-12 Schering Corp Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos
AU2005265031A1 (en) 2004-06-17 2006-01-26 Forest Laboratories, Inc. Modified release formulation of memantine
DE502005008916D1 (de) 2004-07-23 2010-03-11 Medicines Co Leipzig Gmbh Substituierte pyridoä3',2':4,5üthienoä3,2-düpyrimidine und pyridoä3',2':4,5üfuroä3,2-dü-pyrimidine zur verwendung als inhibitoren der pda-4 und/oder tnf-alpha freisetzung
EP1778687A2 (en) 2004-07-27 2007-05-02 SGX Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
CN100381175C (zh) 2004-10-09 2008-04-16 山西中医学院 一种微乳制剂及其制备方法
NZ555566A (en) 2004-11-22 2009-12-24 Vertex Pharma Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
SI1838677T1 (sl) 2004-12-21 2010-01-29 Arena Pharm Inc Kristalne oblike (R)-8-kloro-1-metil-2,3,4,5-tetrahidro-1H-3-benzazepin hidroklorida
US7947695B2 (en) 2005-01-14 2011-05-24 Janssen Pharmaceutica Nv 5-membered annelated heterocyclic pyrimidines as kinase inhibitors
AU2006205850A1 (en) 2005-01-14 2006-07-20 Janssen Pharmaceutica N.V. Pyrazolopyrimidines as cell cycle kinase inhibitors
US20060183758A1 (en) 2005-02-17 2006-08-17 Cb Research And Development, Inc. Method for synthesis of AZA-annelated pyrroles, thiophenes, and furans
EP1863813A2 (en) 2005-04-01 2007-12-12 Coley Pharmaceutical Group, Inc. Pyrazolo[3,4-c]quinolines, pyrazolo[3,4-c]naphthyridines, analogs thereof, and methods
US7737279B2 (en) 2005-05-10 2010-06-15 Bristol-Myers Squibb Company 1,6-dihydro-1,3,5,6-tetraaza-as-indacene based tricyclic compounds and pharmaceutical compositions comprising same
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
EP2251341A1 (en) 2005-07-14 2010-11-17 Astellas Pharma Inc. Heterocyclic Janus kinase 3 inhibitors
JP5071374B2 (ja) 2005-07-14 2012-11-14 アステラス製薬株式会社 ヘテロ環ヤヌスキナーゼ３阻害剤
CA2619049A1 (en) 2005-08-16 2007-02-22 Irm, Llc Compounds and compositions as protein kinase inhibitors
CA2622677A1 (en) * 2005-09-23 2007-04-05 Richard Schumacher Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
US20090240055A1 (en) 2005-09-23 2009-09-24 Krepski Larry R Method for 1H-Imidazo[4,5-C] Pyridines and Analogs Thereof
US8106066B2 (en) * 2005-09-23 2012-01-31 Memory Pharmaceuticals Corporation Indazoles, benzothiazoles, benzoisothiazoles, benzisoxazoles, pyrazolopyridines, isothiazolopyridines, and preparation and uses thereof
ES2390135T3 (es) 2005-11-22 2012-11-06 Merck Sharp & Dohme Corp. Compuestos tricíclicos útiles como inhibidores de quinasas
JP5512975B2 (ja) 2005-12-29 2014-06-04 アッヴィ・インコーポレイテッド タンパク質キナーゼ阻害薬
BRPI0709880A2 (pt) 2006-04-03 2011-07-26 Hoffmann La Roche processo para preparaÇço e Ácidos carboxÍlicos cÍclicos beta-arÍlicos ou heteroarÍlicos e-nantiomericamente enriquecidos
JP5386350B2 (ja) 2006-05-31 2014-01-15 タケダ カリフォルニア インコーポレイテッド グルコキナーゼ活性剤としての、インダゾールおよびイソインドール誘導体
US8063225B2 (en) 2006-08-14 2011-11-22 Chembridge Corporation Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders
CA2660476C (en) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations of flibanserin and method for manufacturing the same
EP2068869A4 (en) 2006-10-06 2011-05-25 Abbott Lab NEW IMIDAZOTHIAZOLE AND IMIDAZOXAZOLE
CA2675288A1 (en) 2007-01-12 2008-07-17 Astellas Pharma Inc. Condensed pyridine compound
CN101230059B (zh) * 2007-01-23 2011-08-17 上海恒瑞医药有限公司 双环氮杂烷类衍生物、其制备方法及其在医药上的用途
US20100190787A1 (en) 2007-01-30 2010-07-29 Srinivas Rao Kasibhatla Modulators of Mitotic Kinases
WO2008112695A2 (en) 2007-03-12 2008-09-18 Irm Llc Pyrazolo [3,4-d] pyrimidines and 1, 2, 5, 6-tetraaza- as- indacenes as protein kinase inhibitors for cancer treatment
US7723343B2 (en) 2007-03-30 2010-05-25 King Pharmaceuticals Research And Development, Inc. Adenosine A2A receptor antagonists
WO2008135090A1 (en) 2007-05-07 2008-11-13 Evonik Röhm Gmbh Solid dosage forms comprising an enteric coating with accelerated drug release
EP2152712B1 (en) 2007-05-11 2012-01-11 Pfizer Inc. Amino-heterocyclic compounds
WO2009005675A1 (en) 2007-06-28 2009-01-08 Abbott Laboratories Novel triazolopyridazines
US20090022789A1 (en) 2007-07-18 2009-01-22 Supernus Pharmaceuticals, Inc. Enhanced formulations of lamotrigine
WO2009106445A1 (en) 2008-02-25 2009-09-03 F. Hoffmann-La Roche Ag Pyrrolopyrazine kinase inhibitors
JP5529049B2 (ja) 2008-02-25 2014-06-25 エフ．ホフマン−ラ ロシュ アーゲー ピロロピラジンキナーゼ阻害剤
EP2247592B1 (en) 2008-02-25 2011-08-31 F. Hoffmann-La Roche AG Pyrrolopyrazine kinase inhibitors
WO2009108827A1 (en) 2008-02-29 2009-09-03 Wyeth Fused tricyclic pyrazolo[1, 5-a]pyrimidines, methods for preparation and uses thereof
WO2009118321A1 (de) 2008-03-28 2009-10-01 Boehringer Ingelheim International Gmbh Verfahren zur herstellung von säurepellets
TW201612182A (en) 2008-06-10 2016-04-01 Abbvie Inc Novel tricyclic compounds
JP2011526931A (ja) 2008-07-03 2011-10-20 エグゼリクシス， インコーポレイテッド Ｃｄｋモジュレーター
CN101638423B (zh) * 2008-07-29 2012-09-05 常州高新技术产业开发区三维工业技术研究所有限公司 根皮苷衍生物及其制备方法和用途
PT2401269E (pt) 2009-02-24 2014-03-11 Merck Canada Inc Derivados de indol como antagonistas de recetor crth2
WO2010117796A2 (en) 2009-03-30 2010-10-14 Codexis, Inc. Processes for the preparation of alpha-chloroketones from carboxylic acids
US20120034250A1 (en) 2009-04-14 2012-02-09 Astellas Pharma Inc. Condensed pyrrolopyridine derivative
CN101904814A (zh) 2009-06-04 2010-12-08 上海恒瑞医药有限公司 制备载药乳剂的方法
FR2947276B1 (fr) 2009-06-24 2012-10-26 Seppic Sa Composition cosmetique a base de resines echangeuses d'ions chargees avec des lipoaminoacides
US8361962B2 (en) 2009-07-27 2013-01-29 Roche Palo Alto Llc Tricyclic inhibitors of JAK
EP2459180A1 (en) 2009-07-31 2012-06-06 Ranbaxy Laboratories Limited Multi-layered, multiple unit pharmaceutical compositions
AU2010326030A1 (en) 2009-12-01 2012-06-07 Abbvie Inc. Novel tricyclic compounds
CN102711476B (zh) 2009-12-01 2014-12-03 Abbvie公司 新的三环化合物
WO2011141791A2 (en) 2010-05-14 2011-11-17 Alembic Limited Extended release formulations of desvenlafaxine base
TW201201801A (en) 2010-06-09 2012-01-16 Presidio Pharmaceuticals Inc Inhibitors of HCV NS5A protein
US8637529B2 (en) 2010-06-11 2014-01-28 AbbYie Inc. Pyrazolo[3,4-d]pyrimidine compounds
JP5998142B2 (ja) 2010-09-27 2016-09-28 アボット ゲーエムベーハー ウント カンパニー カーゲー 複素環化合物およびグリコーゲンシンターゼキナーゼ−３阻害薬としてのその使用
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
US20120330012A1 (en) 2011-04-29 2012-12-27 Abbott Laboratories Novel Tricyclic Compounds
US20130072470A1 (en) * 2011-09-21 2013-03-21 Abbvie Inc. Novel tricyclic compounds
FR2991171B1 (fr) 2012-06-01 2014-05-23 Galderma Res & Dev Procede de preparation d'une composition dermatologique comprenant des oleosomes
WO2014004863A2 (en) 2012-06-27 2014-01-03 Alzheimer's Institute Of America, Inc. Compounds, compositions, and therapeutic uses thereof
BR112015021980A2 (pt) 2013-03-15 2017-07-18 Global Blood Therapeutics Inc compostos e seus usos para a modulação de hemoglobina
JP6041823B2 (ja) 2013-03-16 2016-12-14 ファイザー・インク トファシチニブの経口持続放出剤形
US20150118229A1 (en) 2013-10-24 2015-04-30 Abbvie Inc. Jak1 selective inhibitor and uses thereof
CN106794126A (zh) 2014-08-27 2017-05-31 艾伯维公司 局部配制品
JP6796083B2 (ja) 2015-06-09 2020-12-02 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップＣａｐｓｕｇｅｌ Ｂｅｌｇｉｕｍ ＮＶ カプセル中の薬剤の噴霧乾燥ディスパーションからの迅速な溶解を達成するための製剤
WO2017025849A1 (en) 2015-08-13 2017-02-16 Pfizer Inc. Bicyclic-fused heteroaryl or aryl compounds
ES2865199T3 (es) 2015-08-27 2021-10-15 Pfizer Compuestos de heteroarilo o arilo condensados bicíclicos como moduladores de IRAK4
US11512092B2 (en) 2015-10-16 2022-11-29 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
EP3362455A1 (en) 2015-10-16 2018-08-22 AbbVie Inc. PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOF
US11524964B2 (en) 2015-10-16 2022-12-13 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-n-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US11365198B2 (en) 2015-10-16 2022-06-21 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
US10550126B2 (en) 2015-10-16 2020-02-04 Abbvie Inc. Processes for the preparation of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-A]pyrrolo[2,3-e]-pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide and solid state forms thereof
WO2017093857A1 (en) 2015-11-30 2017-06-08 Anacor Pharmaceuticals, Inc. Topical pharmaceutical formulations for treating inflammatory-related conditions
WO2017126488A1 (ja) 2016-01-18 2017-07-27 持田製薬株式会社 乾癬治療用組成物および治療方法
WO2017143014A1 (en) 2016-02-16 2017-08-24 Brian Kim Jak inhibitors and uses thereof
JP7258561B2 (ja) 2016-07-06 2023-04-17 オリエント ファーマ シーオー．，エルティーディー． 薬物組成物、バリヤー層及び薬物層を有している経口投与形態
CA3052873A1 (en) 2017-03-09 2018-09-13 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis
US11564922B2 (en) 2017-03-09 2023-01-31 Abbvie Inc. Methods of treating crohn's disease and ulcerative colitis

Also Published As

Publication number Publication date
US20230331735A1 (en) 2023-10-19
US11780847B1 (en) 2023-10-10
US20240034740A1 (en) 2024-02-01
US11773105B2 (en) 2023-10-03
JP2019501865A (ja) 2019-01-24
US20220298165A1 (en) 2022-09-22
US20230058001A1 (en) 2023-02-23
SG10201913993QA (en) 2020-03-30
CN116270646A (zh) 2023-06-23
US10981923B2 (en) 2021-04-20
US20180186805A1 (en) 2018-07-05
SG10201913999PA (en) 2020-03-30
US9963459B1 (en) 2018-05-08
BR122022024925B1 (pt) 2023-11-28
AU2021236570A1 (en) 2021-10-28
CA3123260A1 (en) 2017-04-20
US9879019B2 (en) 2018-01-30
RU2018117889A (ru) 2019-11-20
US10202393B2 (en) 2019-02-12
EP4219503A1 (en) 2023-08-02
SG10201913986YA (en) 2020-03-30
US11787815B1 (en) 2023-10-17
US20190315761A1 (en) 2019-10-17
KR20180081523A (ko) 2018-07-16
AU2021236570B2 (en) 2023-11-02
US11661425B2 (en) 2023-05-30
JP7358317B2 (ja) 2023-10-10
CN108368121A (zh) 2018-08-03
US20170129902A1 (en) 2017-05-11
US20210363149A1 (en) 2021-11-25
AU2016340167A1 (en) 2018-04-26
JP2022107001A (ja) 2022-07-20
US9951080B2 (en) 2018-04-24
US10981924B2 (en) 2021-04-20
US20230303582A1 (en) 2023-09-28
US20240010656A1 (en) 2024-01-11
SG10201913997WA (en) 2020-03-30
US20200291040A1 (en) 2020-09-17
US20230312593A1 (en) 2023-10-05
US10344036B2 (en) 2019-07-09
WO2017066775A1 (en) 2017-04-20
US20180162865A1 (en) 2018-06-14
US10730883B2 (en) 2020-08-04
US20230203049A1 (en) 2023-06-29
US11795175B2 (en) 2023-10-24
MX2021013812A (es) 2021-12-14
US11680069B2 (en) 2023-06-20
US9879018B2 (en) 2018-01-30
US20170342083A1 (en) 2017-11-30
SG10201913990RA (en) 2020-03-30
RU2018117889A3 (es) 2020-08-12
US10597400B2 (en) 2020-03-24
JP2021020902A (ja) 2021-02-18
AU2023251492A1 (en) 2023-11-09
US20200317682A1 (en) 2020-10-08
CN108368121B (zh) 2023-01-13
US20230183257A1 (en) 2023-06-15
CN116284011A (zh) 2023-06-23
IL258654A (en) 2018-06-28
US20180222914A1 (en) 2018-08-09
SG10201913989QA (en) 2020-03-30
US20170362247A1 (en) 2017-12-21
US20230322794A1 (en) 2023-10-12
US20210309667A1 (en) 2021-10-07
SG11201802990RA (en) 2018-05-30
US11198697B1 (en) 2021-12-14
US20230312595A1 (en) 2023-10-05
US11718627B2 (en) 2023-08-08
CN116270645A (zh) 2023-06-23
EP3362455A1 (en) 2018-08-22
IL283531A (en) 2021-07-29
BR112018007677A2 (pt) 2018-11-06
CA3002220A1 (en) 2017-04-20
US11535624B2 (en) 2022-12-27
US20190023714A1 (en) 2019-01-24
US20180141955A1 (en) 2018-05-24
US11186584B2 (en) 2021-11-30
AU2016340167B2 (en) 2021-06-24
US20180222913A1 (en) 2018-08-09
US20230057084A1 (en) 2023-02-23
CA3002220C (en) 2021-07-20
US10519164B2 (en) 2019-12-31
US10202394B2 (en) 2019-02-12
US20200181158A1 (en) 2020-06-11
US20180057502A1 (en) 2018-03-01
SG10201913987UA (en) 2020-03-30
US20230219968A1 (en) 2023-07-13
US20230374027A1 (en) 2023-11-23
AU2016340167A8 (en) 2018-05-10
HK1263380A1 (zh) 2020-05-29
US20190322677A1 (en) 2019-10-24
US20230348481A1 (en) 2023-11-02
US10017517B2 (en) 2018-07-10
JP2023113917A (ja) 2023-08-16
US20200361949A1 (en) 2020-11-19
JP6770775B2 (ja) 2020-10-21

Similar Documents

Publication Publication Date Title
MX2021013812A (es) Procesos para la preparacion de (3s,4r)-3-etil-4-(3h-imidazo[1,2-a ]pirrolo[2,3-e]-pirazin-8-il)-n-(2,2,2-trifluoroetil) pirrolidin-1-carboxamida y formas en estado solido de la misma.
PH12017501340A1 (en) 4h-pyrrolo[3,2-c]pyridin-4-one derivatives
MY164274A (en) Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof
WO2013077921A3 (en) Substituted pyrazolo[3,4-d]pyrimidines and uses thereof
WO2016007617A3 (en) Pharmaceutical compounding kit
MY193728A (en) Muscarinic receptor agonists
CL2011000668A1 (es) Compuestos derivados de pirazolopiridina; proceso de preparacion; composicion farmaceutica y uso en el tratamiento de enfermedades tales como artritis reumatoide, psoriasis, esclerosis multiple, entre otras.
PH12016502307B1 (en) Alkyl derivatives of 1-oxa-4,9-diazaspiro undecane compounds having multimodal activity against pain
EP3250572A4 (en) Substituted imidazo [1, 2-a]pyridin-2-ylamine compounds, and pharmaceutical compositions and methods of use thereof
WO2014001822A3 (en) In vitro production of cyclic peptides
MX2018011970A (es) Formas sólidas de (1s,4s)-4-(2-(((3s,4r)-3-fluorotetrahidro-2h-pir an-4-il)amino)-8-((2,4,6-triclorofenilo)amino)-9h-purin-9-il)-1-m etilciclohexano-1-carboxamida y métodos para utilizarlas.
PH12018500796A1 (en) Cyclic ether derivatives of pyrazolo[1,5-a] pyrimidine-3-carboxamide
AU2013212209A8 (en) (1R,4R) 7-oxo-2-azabicyclo[2.2.2]oct-5-ene and derivatives thereof
IN2014KN02722A (es)
MX2017006513A (es) Compuestos de tipo 1,9-diazaespiroundecano con actividad multimodal contra el dolor.
WO2012122451A3 (en) Polymorphs of maxacalcitol and process for the preparation of maxacalcitol
WO2014193881A8 (en) Crystalline form of n,n-dicyclopropyl-4-(1,5-dimethyl-1 h-pyrazol-3-ylamino)-6-ethyl-1 -methyl-1,6-dihyrdroimidazo[4,5-d]pyrrolo[2,3-b]pyridine-7-carboxamide for the treatment of myeloproliferative disorders
PH12019550048A1 (en) Crystalline polymorphs of a muscarinic acetylcholine receptor agonist
LV14663A (lv) Pirolo[1,2-a]hinazolīna atvasinājumu sintēze no N-antranilskābes hidrazīdiem un alfa-ketoskābēm
TN2013000146A1 (en) Salt(s) of 7-cyclopentyl-2 -(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof